On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma. To listen to more podcasts from ASCO, visit <a href= "https://old-prod.asco.org/news-initiatives/podcasts">asco.org/podcasts</a>.

On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma. To listen to more podcasts from ASCO, visit <a href="https://old-prod.asco.org/news-initiatives/podcasts" rel="noopener noreferrer">asco.org/podcasts</a>.

Share FDA Approvals in Hepatocellular Carcinoma and Multiple Myeloma

Sign up to save your podcasts

FDA Approvals in Hepatocellular Carcinoma and Multiple Myeloma

FDA Approvals in Hepatocellular Carcinoma and Multiple Myeloma

More shows like The ASCO Post Podcast

Research To Practice | Oncology Videos

ASCO Daily News